CBIO - Crescent Biopharma Stock Price, Chart, News and Analysis
CBIO news
Crescent Biopharma, Inc. Common Stock (CBIO): What does the company do?
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Unlock full access
Every scanner, the BH Indicator, insider and options flow, sector and industry rankings, the themes, the trading journal and the daily briefings from the Senior Analyst.
See plans →Breakouts Happen publishes market analysis and screening tools. Every idea, opinion and forecast on this site — stated or implied — is provided for informational purposes only and is not a recommendation to invest, trade or speculate in any market. Any position taken in light of the material published here is taken at your own risk, financial or otherwise. Breakouts Happen is not a registered investment advisor, and nothing on this site is an offer or solicitation to buy or sell any security.
Market data is delayed and provided for reference only. Past performance does not indicate future results.